title: Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
abstract: OBJECTIVE
  The analgesic effect of codeine depends on the formation of the opioid metabolites morphine and morphine-6-glucuronide. Different factors have been shown or suspected to affect the safety and efficacy of codeine treatment. The objective of the current study is to assess and quantify the impact of important pharmacokinetic factors, using a mechanistic modeling approach.
  
  
  METHODS
  By means of a generic modeling approach integrating prior physiologic knowledge, we systematically investigated the complex dependence of opioid exposure on cytochrome P450 2D6 and 3A4 (CYP2D6 and CYP3A4), and uridine diphosphate glucuronosyltransferase 2B7 (UGT2B7) activity, as well as renal function, by means of a virtual clinical trial.
  
  
  RESULTS
  First, the known dominant role of CYP2D6 activity for morphine exposure was reproduced. Second, the model demonstrated that mild and moderate renal impairment and co-administration of CYP3A4 inhibitors have only minor influences on opioid exposure. Third, the model showed - in contrast to current opinion - that increased UGT2B7 activity is associated with a decrease in active opioid exposure.
  
  
  CONCLUSIONS
  Overall, the model-based analysis predicts a wide range of morphine levels after codeine administration and supports recent doubts about safe and efficacious use of codeine for analgesia in non-genotyped individuals.
authors.affiliation: Competence Center Systems Biology and Computational Solutions, Bayer Technology Services GmbH, Leverkusen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Eissing
authors.forename: Jörg
authors.initials: J
authors.lastname: Lippert
authors.forename: Stefan
authors.initials: S
authors.lastname: Willmann
mesh_terms: D000701:Analgesics, Opioid / Q000378:metabolism / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003061:Codeine / Q000378:metabolism / Q000494:pharmacology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism*; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D008954:Models, Biological; D009020:Morphine / Q000378:metabolism / Q000494:pharmacology; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
chemical_list: D000701:Analgesics, Opioid; D065692:Cytochrome P-450 CYP3A Inhibitors; D009020:Morphine; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase; D003061:Codeine